Core Insights - The collaboration between the Luohu District Government and Shenzhen University of Technology aims to establish the "Shenzhen University of Technology Luohu Medical Center" and "Shenzhen University of Technology Luohu Medical Industry Incubation Base" to enhance the life and health industry through innovation in systems and mechanisms [1][2] Group 1: Collaboration Details - The partnership will create a comprehensive "medical research, production, and talent" complex, promoting deep integration of industry, academia, and research [1] - The "one center, one base" initiative is located in the Health Industry Park at the Zhifeng Building in Luohu District, designed to foster an ecosystem for life and health industry services [1] Group 2: Talent and Resource Sharing - The medical center will implement a dual-hire Principal Investigator (PI) talent system to attract top scholars from Shenzhen University of Technology and clinical experts from Luohu, facilitating resource sharing [1] - The collaboration will leverage clinical resources and platform advantages to establish an innovative industry incubation space and a cell therapy drug research and transformation platform [1] Group 3: Operational Model - The incubation base will adopt a "government-led, university-driven, enterprise-operated" model, with Luohu District providing industrial space and entrusting daily operations to professional service agencies [1] - The focus will be on cutting-edge fields such as AI + medical devices, medical-engineering integration, precision medicine, and cell and gene therapy, promoting the integration of medical research and industrial transformation [1][2] Group 4: Data and Impact - Luohu District's medical institutions handle over 10 million diagnoses annually and have accumulated nearly 1000TB of medical data, providing a "technology testing ground" and opportunities for first-use by enterprises [2] - Shenzhen University of Technology, as one of the first new research-oriented universities in China, has a strong capability in scientific research innovation and talent cultivation, which will further enhance the collaborative ecosystem [2]

Core Insights - The AI-enabled Shenzhen Pharmaceutical and Medical Device Industry High-Quality Development Conference successfully took place, focusing on how data and algorithms can enhance drug development, precision medicine, and health management [1] - Shenzhen is a major hub for AI pharmaceutical companies, with 18 AI drug companies representing 17% of the national total, including notable firms like Crystal Technology, Star Pharmaceutical, and Eglen Pharmaceuticals [1] - Shenzhen's AI drug clinical pipelines are advancing rapidly, with 10 AI pipelines entering clinical stages, accounting for 10% globally and 30% nationally [1] - The "AI + Medical Devices" industry in Shenzhen is also leading nationally, with products concentrated in various disease areas such as cardiovascular, neurological, and oncology [1] Product and Data Development - The conference announced a list of outstanding AI + pharmaceutical and medical device products, including high-throughput peptide synthesizers and AI diagnostic models for chronic diseases [2] - The biomedicine and high-end medical device sectors are key strategic emerging industry clusters in Shenzhen, relying on a high-quality data flow environment for digital and intelligent development [2] - Shenzhen Data Exchange introduced five high-quality medical data products focused on public health, chronic disease management, and vaccination, providing a solid data foundation for AI pharmaceutical companies [2] - The Shenzhen Data Exchange has made breakthroughs in data property registration, trusted circulation, and revenue distribution, creating replicable and scalable innovative results in various fields, including healthcare [2]